A complicated liaison: IL-33 and IL-33R in arthritis pathogenesis

Interruption of cytokine signaling, by targeting either the cytokine itself or its cellular receptor, is a mainstay in the therapy for patients with rheumatic diseases. Interleukin (IL)-33, a member of the IL-1 cytokine family, has emerged as an important mediator of inflammatory responses. In a side-by-side examination of IL-33-deficient and IL-33 receptor (IL-33R)-deficient mice in the K/BxN serum transfer model, arthritis was ameliorated in the IL-33R knockout (KO) mice but not in the IL-33 KO mice. These findings complement previous knowledge on IL-33R signaling, demonstrating that the IL-33R cross-activates other signaling pathways in addition to IL-33-mediated signals. The results reported by Martin and colleagues in a previous issue of Arthritis Research & Therapy underline the clinical relevance of IL-33R cross-signaling and further illustrate that targeting a cytokine receptor (IL-33R) can have completely different clinical outcomes than targeting the respective cytokine.

• Publication year

  2013

• Venue

  Arthritis Research & Therapy

• Publication date

  2013-05-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/ar4209PMID 23638884PMCID 3672742
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency

  2013influential reference
• The need for littermate controls

  2012cited by this paper
• IL-33 Shifts the Balance from Osteoclast to Alternatively Activated Macrophage Differentiation and Protects from TNF-α–Mediated Bone Loss

  2011cited by this paper
• The biological paths of IL‐1 family members IL‐18 and IL‐33

  2011influential reference
• Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway

  2011cited by this paper
• IL-33 Exacerbates Autoantibody-Induced Arthritis

  2010cited by this paper
• IL-33 and IL-33 receptors in host defense and diseases.

  2010influential reference
• The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells.

  2010cited by this paper
• Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

  2009cited by this paper
• IL-33 exacerbates antigen-induced arthritis by activating mast cells

  2008influential reference
• Interleukin 18–independent engagement of interleukin 18 receptor-α is required for autoimmune inflammation

  2006cited by this paper
• The role and clinical implications of G6PI in experimental models of rheumatoid arthritis

  2004cited by this paper
• ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance

  2004cited by this paper
• Regulation and Function of T1/ST2 Expression on CD4+ T Cells: Induction of Type 2 Cytokine Production by T1/ST2 Cross-Linking1

  2001cited by this paper

• Blocking Interleukin-33 Alleviates the Joint Inflammation and Inhibits the Development of Collagen-Induced Arthritis in Mice

  2020cites this paper
• Dual immune functions of IL-33 in inflammatory bowel disease.

  2020cites this paper
• Nuclear Alarmin Cytokines in Inflammation

  2020cites this paper
• Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis

  2018cites this paper
• Gegenseitige Beeinflussung von Immunsystem und Knochen

  2018cites this paper
• A review on interleukins: The key manipulators in rheumatoid arthritis

  2017cites this paper
• In Vivo Expansion of Activated Foxp3+ Regulatory T Cells and Establishment of a Type 2 Immune Response upon IL-33 Treatment Protect against Experimental Arthritis

  2016cites this paper
• Effects and mechanisms of potent caspase-1 inhibitor VX765 treatment on collagen-induced arthritis in mice.

  2016cites this paper
• TNF-α Regulating Interleukin-33 Induces Acute Pancreatic Inflammation in Rats.

  2016cites this paper
• ACTIVATION OF HUMAN MAST CELLS TO DOWN- REGULATE MONOCYTE-MEDIATED IMMUNE RESPONSES Chapter 6

  2016cites this paper
• Ability of Interleukin‐33– and Immune Complex–Triggered Activation of Human Mast Cells to Down‐Regulate Monocyte‐Mediated Immune Responses

  2015cites this paper
• IL-33/ST2 axis promotes mast cell survival via BCLXL

  2014cites this paper